DMRA · Damora Therapeutics, Inc.
$32.44
+0.64 (+2.01%)
At close · Aug 19
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If we are unable to raise additional capital when needed, that could raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 10, 2026
Market Cap
$1.97B
Shares
61.74M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Key facts
CIK
1800315
CUSIP
G2646Y104
13F (30d)
104 filings
103 filers
Visit website
Investor relations